PMID: 11932906Apr 5, 2002Paper

Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population

Cancer
Jeremy G PerkinsJohn C Byrd

Abstract

Treatments for fludarabine-refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) are limited. Most new therapies being examined in fludarabine-refractory patients have shown a high frequency of serious infection. Little data exist regarding the frequency of infections in this population treated with noninvestigational best supportive care therapies. The infectious courses of 27 patients with fludarabine-refractory CLL/SLL were retrospectively reviewed. Fludarabine-refractoriness was defined as either relapse within six months of completion of or failure to respond to fludarabine treatment. Infections were documented after patients met National Cancer Institute criteria for further treatment. Serious infections were defined as infections mandating admission to the hospital for intravenous antibiotics. Patient characteristics included: median age 67 years (range, 40-83), median 3 chemotherapy treatments (range, 1-8), and hypogammaglobulinemia in 73% of patients. Pneumocystis carinii prophylaxis was given to 89% of patients. Serious infections developed in 24 out of 27 patients (89%). Patients had a median of 2 admissions (range, 0-11) for serious infection occurring at a median of 4 months (range, 0-21) f...Continue Reading

Citations

Apr 30, 2005·Cell Death and Differentiation·M MacFarlaneG M Cohen
Nov 17, 2006·Leukemia·P DregerUNKNOWN Chronic Leukemia Working Party of the EBMT
Jan 7, 2014·Current Hematologic Malignancy Reports·Julie E Chang, Brad S Kahl
Sep 17, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mohamed L SorrorDavid G Maloney
Mar 16, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Philip C AmreinJennifer R Brown
Jan 1, 2010·Mediterranean Journal of Hematology and Infectious Diseases·Luca LaurentiSimona Sica
Apr 19, 2011·Clinical Medicine Insights. Oncology·Chadi Nabhan, Neil E Kay
Mar 6, 2012·European Journal of Internal Medicine·Juan José AlonsoCiriaco Aguirre
Aug 1, 2009·Blood Reviews·Julio DelgadoJorge Sierra
Oct 20, 2005·Clinical Lymphoma & Myeloma·Chadi Nabhan
Apr 10, 2004·Clinical Lymphoma·Michael KeatingPeter Hillmen
Aug 21, 2007·Best Practice & Research. Clinical Haematology·Constantine S Tam, Michael J Keating
Aug 12, 2003·Cancer·Alessandra FerrajoliMichael J Keating
Apr 17, 2004·British Journal of Haematology·D OscierUNKNOWN Guidelines Working Group of the UK CLL Forum. British Committee for Standards in Haematology
Feb 3, 2009·British Journal of Haematology·John G Gribben, Michael Hallek
Jun 21, 2005·Blood Reviews·Farhad Ravandi, Susan O'Brien
May 25, 2006·Seminars in Oncology·Anders OsterborgHåkan Mellstedt
Jul 23, 2004·Seminars in Hematology·Jeanette Lundin, Anders Osterborg
Oct 30, 2010·Clinical Lymphoma, Myeloma & Leukemia·Susan O'Brien, Anders Osterborg
Oct 18, 2011·Clinical Lymphoma, Myeloma & Leukemia·Karam M ObeidLeonard B Johnson
Jul 29, 2006·Expert Opinion on Pharmacotherapy·Thomas ElterAndreas Engert

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.